- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03171142
Effect of Heliox on RSV Bronchiolitis
May 26, 2017 updated by: Wael Seliem
Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study
Helium is an inert gas with a density almost one-seventh of that of air.
Based on its properties breathing a mixture of helium and oxygen (heliox) will lead to a reduction in resistance through narrowed airways and consequently decreases the work of breathing.
Participating infants with RSV acute bronchiolitis will be supplied with heliox (ration of 21 oxygen and 79 helium) delivered through a flow nasal cannula to evaluate heliox effect in improving their oxygenation.
Heliox will act as an additive therapy to improve oxygenation in patients with lower respiratory tract infection caused by respiratory Syncytial Virus (RSV) and will decrease the need for more complicated therapies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
104
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 2 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age fro 1 month till 2 years
- RSV acute bronchiolitis without any supplemental oxygen.
Exclusion Criteria:
- oxygen supplement or mechanical ventilation requirement
- congenital anomalies of the heart
- chronic lung disease including bronchopulmonary dysplasia
- Failure to obtain an informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Heliox group
receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
|
Heliox (21:79) via nasal cannula 2 litter per minutes
|
Active Comparator: Air group
receive oxygen 21%via nasal cannula 2L/min
|
Air 21% via nasal cannula 2 litter per minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in oxygenation
Time Frame: change from baseline at 24 hours after treatment
|
Arterial blood samples will be withdrawn through an arterial stab to determine partial pressure of arterial oxygen (PaO2)
|
change from baseline at 24 hours after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
improvement of respiratory distress
Time Frame: change from baseline at 24 hours after treatment
|
measured by the Modified Wood's Clinical Asthma Score
|
change from baseline at 24 hours after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2015
Primary Completion (Actual)
August 1, 2016
Study Completion (Actual)
May 1, 2017
Study Registration Dates
First Submitted
May 24, 2017
First Submitted That Met QC Criteria
May 26, 2017
First Posted (Actual)
May 31, 2017
Study Record Updates
Last Update Posted (Actual)
May 31, 2017
Last Update Submitted That Met QC Criteria
May 26, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bronchial Diseases
- Paramyxoviridae Infections
- Mononegavirales Infections
- Lung Diseases, Obstructive
- Pneumovirus Infections
- Bronchitis
- Respiratory Syncytial Virus Infections
- Bronchiolitis
Other Study ID Numbers
- R/17.01.55
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on RSV Infection
-
Biota Pharma Europe LimitedCompletedRespiratory Syncytial Virus (RSV) InfectionUnited Kingdom
-
Gilead SciencesCompletedRespiratory Syncytial Virus (RSV)United States, Belgium, Canada, Netherlands, Australia, Germany, United Kingdom, France
-
Institute for Clinical Effectiveness, JapanGlaxoSmithKlineRecruitingAcute Disease | Respiratory Syncytial Virus (RSV) | Respiratory Viral InfectionJapan
-
Imperial College LondonRecruitingRSV InfectionUnited Kingdom
-
Bavarian NordicCompletedRSV InfectionUnited Kingdom
-
Meissa Vaccines, Inc.HvivoCompleted
-
Enanta Pharmaceuticals, InchVIVO Services LimitedCompleted
-
HvivoGlaxoSmithKlineCompleted
-
Hospices Civils de LyonUnknownRespiratory Syncytial Virus Infections | RSV Infection | Syncytial Virus Respiratory Infection | RSV Bronchiolitis
-
Enanta Pharmaceuticals, IncRecruitingRSV InfectionUnited States, Poland, Spain, Taiwan, Bulgaria, Argentina, Puerto Rico, Czechia, Brazil, Israel, Malaysia, Netherlands, Slovakia, South Africa
Clinical Trials on Heliox
-
Case Western Reserve UniversityTerminatedBronchiolitis | Pediatrics | HelioxUnited States
-
Centre Hospitalier Universitaire de NiceTerminatedHealthy VolunteersFrance
-
Third Military Medical UniversityCompleted
-
University of Witten/HerdeckeCompleted
-
Northwell HealthStaten Island University HospitalCompletedObstructive Sleep Apnea SyndromeUnited States
-
Poznan University of Medical SciencesCompletedMeconium Aspiration SyndromePoland
-
Hawaii Pacific HealthHawaii Community Foundation; Hawaii Medical Service AssociationCompletedRespiratory Distress Syndrome, NewbornUnited States
-
Poznan University of Medical SciencesEuropean Society for Paediatric ResearchCompletedRespiratory Distress Syndrome | Premature InfantsPoland
-
Daping Hospital and the Research Institute of Surgery...Unknown
-
Unity Health TorontoUnknownC.Surgical Procedure; CardiacCanada